Jefferies Upgrades Supernus Pharmaceuticals To Buy

Analysts at Jefferies upgraded

from Hold to Buy. The price target for Supernus Pharmaceuticals has been raised from $11.00 to $18.00. Supernus Pharmaceuticals shares have gained 51.32 percent over the past 52 weeks, while the S&P 500 index has surged 7.19 percent in the same period. Supernus Pharmaceuticals' shares fell 5.27 percent to close at $16.01 yesterday.